The aim of the present study was to investigate the association between somatic health and former abuse of AAS in former elite male athletes 30 years after the end of their active sports career.
Retrospective follow-up study.
N = 996 former elite male athletes were sent a questionnaire concerning sociodemographic variables, previous and past sport activity and lifetime prevalence of seeking professional help for health problems. N = 683 (68.6%) answered the questionnaire. The lifetime prevalence of AAS-abuse was 21% (n = 143), while 79% (n = 540) did not admit having ever used AAS.
Former AAS-abuse was associated with tendon ruptures (p = 0.01), depression (p = 0.001), anxiety (p = 0.01) and lower prevalence of prostate hypertrophy (p = 0.01) and decreased libido (p = 0.01). Former advanced AAS-abusers had higher anxiety (p = 0.004) compared to the former less advanced AAS-abusers. Moreover, former advanced AAS-abusers, compared to AAS-naïves, reported more psychiatric problems (p = 0.002), depression (p = 0.003) and anxiety (p = 0.00).
A former AAS-abuse seems to be associated with some somatic and mental health problem, although a former less advanced AAS-abuse is related to lower incidence of prostate hypertrophy. The results raise the question whether some of these associations might be dose- and frequency dependent. These findings should however be seen as hypothesis generating and further studies are needed.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Science and Medicine in Sport
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Anabolic steroids in sport: biochemical, clinical and analytical perspectives.Ann Clin Biochem. 2003; 40: 321-356
- Increased premature mortality of competitive powerlifters suspected to have used anabolic agents.Int J Sports Med. 2000; 21: 225-227
- Doping with anabolic androgenic steroids (AAS): adverse effects on non-reproductive organs and functions.Rev Endocr Metab Disord. 2015; 16: 199-211
- MECHANISMS IN ENDOCRINOLOGY: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions.Eur J Endocrinol. 2015; 173: R47-R58
- Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters.Am J Med Sci. 1992; 303: 78-82
- Impact of single-dose nandrolone decanoate on gonadotropins, blood lipids and HMG CoA reductase in healthy men.Andrologia. 2016; 48: 595-600
- Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS).J Sci Med Sport. 2003; 6: 307-312
- Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature.Vasc Health Risk Manag. 2008; 4: 1475-1480
- Pulmonary embolism associated with the use of anabolic steroids.Eur J Intern Med. 2008; 19: 214-215
- Indirect androgen doping by oestrogen blockade in sports.Br J Pharmacol. 2008; 154: 598-605
- Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes.Arch Gen Psychiatry. 1994; 51: 375-382
- Anabolic steroids and male infertility: a comprehensive review.BJU Int. 2011; 108: 1860-1865
- Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.J Clin Endocrinol Metab. 1990; 70: 282-287
- Androgenic anabolic steroid abuse and the cardiovascular system.Handb Exp Pharmacol. 2010; : 411-457
- Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?.Drug Alcohol Depend. 2008; 98: 1-12
- Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?.Heart. 2004; 90: 496-501
- Increased mortality rate and suicide in Swedish former elite male athletes in power sports.Scand J Med Sci Sports. 2014; 24: 1000-1005
- A retrospective 30-year follow-up study of former Swedish-elite male athletes in power sports with a past anabolic androgenic steroids use: a focus on mental health.Br J Sports Med. 2013; 47: 965-969
- An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies.Ann Clin Psychiatry. 2003; 15: 121-130
- Steroid use among adolescents: findings from Project EAT.J Adolesc Health. 2002; 30: 243-252
- Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users.Clin J Sport Med. 1995; 5: 25-31
- Anabolic steroid use and associated health risk behaviours.Sports Med. 1996; 21: 251-255
- Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use.J Forensic Sci. 2003; 48: 646-651
- First case of fatal pulmonary peliosis without any other organ involvement in a young testosterone abusing male.Forensic Sci Int. 2009; 186: e13-e16
- Anabolic steroids in COPD: a review and preliminary results of a randomized trial.Chron Respir Dis. 2008; 5: 169-176
- Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.Endocr Rev. 2014; 35: 341-375
- Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.BJU Int. 2017; 119: 216-224
- Anabolic steroids and cardiovascular risk: a national population-based cohort study.Drug Alcohol Depend. 2015; 152: 87-92
- Mortality and longevity of elite athletes.J Sci Med Sport. 2010; 13: 410-416
Published online: March 21, 2017
Accepted: March 13, 2017
Received in revised form: February 13, 2017
Received: April 25, 2016
© 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.